Company / Revenue
Voyager Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$250.0M
FY2025
5-year range
$37.4M / $250.0M
FY2021-FY2025
Trend
+511.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue changed +511% YoY in FY2025, a notable deviation from the 9-year average annual change of +189%.
Based on SEC 10-K filings.
$250M in FY2025 with a 5-year CAGR of +101.0%.
Improved from $37M to $250M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +13.5%
- 5-Year CAGR
- +101.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +101.0%, indicating consistent growth.
- In FY2025, revenue increased 511.2% year-over-year.
- Lowest revenue in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $250.0M | +511.2% |
| FY2024 | $40.9M | +9.3% |
| FY2023 | $37.4M | -78.1% |
| FY2022 | $171.1M | +63.9% |
| FY2021 | $104.4M | +1270.1% |
| FY2020 | $7.6M | -24.8% |
| FY2019 | $10.1M | -28.7% |
| FY2018 | $14.2M | -18.0% |
| FY2017 | $17.3M | +0.0% |
| FY2016 | $17.3M | +572.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026